Trial Profile
An observational, prospective study investigating the efficacy of switch to a dual regimen of raltegravir plus darunavir/ritonavir in patients with HIV-1 infections on stable combination antiretroviral therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Feb 2016
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Raltegravir (Primary) ; Ritonavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 16 Feb 2016 New trial record
- 05 Jan 2016 Results were published in HIV Clinical Trials.